Company Overview

Update
Headquarters:
New York, NY
IPO:
Went Public on Jan 5, 2006
Stock:
IMNP
Categories:
Biotechnology
Description:
Immune Pharmaceuticals Inc. (NASDAQ OMX First North Premier: IMNP; OTCQX: IMNP,) applies a personalized approach to treatment, developing

Detailed Description

Update

Immune Pharmaceuticals Inc. (NASDAQ OMX First North Premier: IMNP; OTCQX: IMNP,) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The company’s lead product candidate, Bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma.

Current Team (2)

Update

Funding Rounds (1) - $11.7M

Update

Offices/Locations (1)

Update
  • Office

    708 third avenue

    Suite 210

    New York, NY 10017

    USA

Images (1)

Update
  • 26a509eaf70f038188d34ddf503879bc